[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533749":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":23,"locations":31,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Adult patients with CML in chronic phase (CML-CP)",null,[12],"Other: Interview",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Interview","In-person interview with the study coordinator to complete study questionnaire.",[9],[19],{"name":20,"affiliation":21,"role":22},"Mahtab Jafari, Pharm.D","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":10},"University of California Irvine Medical",[32],{"facility":25,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Orange","California","92868","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-117.85311,33.78779,{"lat":43,"lon":42},[46],{"name":20,"role":26,"phone":47,"phoneExt":10,"email":28},"877-827-8839",{"type":22,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Mahtab Jafari","Professor of Pharmaceutical Sciences & Equity Advisor","100533749","impact-of-personality-on-adherence-to-tyrosine-kinase-inhibitor-therapy-in-pts-wchronic-myeloid-leukemia-100533749",false,"NCT06229860","Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w\u002FChronic Myeloid Leukemia","Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia","Inclusion Criteria:\n\n* 18 years of age or older\n* Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)\n* Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib\n* A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or\n* A member of a patient support group organized by the CML Buster Foundation\n* Do not meet any of the criteria listed under \"Exclusion Requirements\"\n\nExclusion Criteria:\n\n* Unable to read and speak English\n* Impaired decisional capacity to consent","ALL","18 Years",{"count":61,"type":62},75,"ESTIMATED","OBSERVATIONAL","This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.",[66,67],"Chronic Myeloid Leukemia","Chronic Phase Chronic Myelogenous Leukemia","2026-03-06",{"date":70,"type":71},"2026-03-10","ACTUAL",{"date":73,"type":71},"2024-01-25",{"date":75,"type":62},"2026-12",{"name":5,"class":6},1]